Drugs / AH-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06927960 | Mar → Jul 2025 | androgenetic alopecia | AnHorn Medicines Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-30 | AnHorn Medicines Co. Ltd. | Results AI-Designed Drug AH-001 Complete U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability anhornmed.com ↗
The trial confirmed that AH-001 was safe and well-tolerated across all dose levels , with no drug-related adverse events . |
| 2024-11-07 | AnHorn Medicines Co. Ltd. | Regulatory AnHorn Medicines Achieves IND Clearance for AH-001 Protein Degrader Targeting Androgenetic Alopecia, First IND Milestone in 4 Years anhornmed.com ↗
We are thrilled to achieve IND clearance for AH-001, a milestone that exemplifies the speed and impact of our AI-accelerated discovery platform, and our team’s exceptional capability and commitment. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-30 | AnHorn Medicines Co. Ltd. | AI-Designed Drug AH-001 Complete U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability anhornmed.com ↗ |
| 2025-03-27 | AnHorn Medicines Co. Ltd. | AnHorn Medicines Announces First Subject Dosed in AH-001 Phase I Clinical Trial in the United States anhornmed.com ↗ |
| 2024-11-07 | AnHorn Medicines Co. Ltd. | AnHorn Medicines Achieves IND Clearance for AH-001 Protein Degrader Targeting Androgenetic Alopecia, First IND Milestone in 4 Years anhornmed.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AH-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06927960 ↗ |
| Route | Topical | “Following Topical Single and Multiple Ascending Dose Administration” NCT06927960 ↗ |